Javascript must be enabled to continue!
The Role of the Clinical Pharmacist in A Case of Losartan-Induced Faintness and Dysarthria
View through CrossRef
Background: A common first-line antihypertensive the medication losartan has excellent absorption after being taken orally and undergoes extensive first-pass metabolic processes. Losartan commonly produces feelings of dizziness, headaches, lethargy, nausea, vomiting, impaired vision, and anaemia as side effects. Case summary: We discuss the case of a 59-year-old Yemeni lady who consumed losartan and had fainting and dysarthria. The patient was started on 50 mg daily oral losartan monotherapy for mild hypertension. After 12 days of utilizing the medication, she relocated to the emergency department in Saudi German Hospital in Sana’a city with dizziness, faintness, dysarthria, lightheadedness with generalized weakness. The in-hospital neurological specialist suspected the patient had a transient ischemic attack. On examination, her blood pressure was found to be 150/86, and her heart rate was 72. The patient was treated in the hospital as a stroke patient for five days and discharged with stroke medications. After discharge, on the second day, the patient has the same previous symptoms. Discussion: There was no proof of any other conceivable physiological, infective, naturally occurring, or other pathologic causes of dysarthria, save losartan itself.. A clinical pharmacist discovered adverse drug reaction probability It was "probable" that oral losartan caused the development off fainting and dysarthria in this patient. The drugs for hypertension were changed by the clinical pharmacist to amlodipine 5mg. After 3 days, the patient was stable, and the symptoms resolved. Conclusions: This case report suggests that losartan could induce faintness and dysarthria as side effects
Title: The Role of the Clinical Pharmacist in A Case of Losartan-Induced Faintness and Dysarthria
Description:
Background: A common first-line antihypertensive the medication losartan has excellent absorption after being taken orally and undergoes extensive first-pass metabolic processes.
Losartan commonly produces feelings of dizziness, headaches, lethargy, nausea, vomiting, impaired vision, and anaemia as side effects.
Case summary: We discuss the case of a 59-year-old Yemeni lady who consumed losartan and had fainting and dysarthria.
The patient was started on 50 mg daily oral losartan monotherapy for mild hypertension.
After 12 days of utilizing the medication, she relocated to the emergency department in Saudi German Hospital in Sana’a city with dizziness, faintness, dysarthria, lightheadedness with generalized weakness.
The in-hospital neurological specialist suspected the patient had a transient ischemic attack.
On examination, her blood pressure was found to be 150/86, and her heart rate was 72.
The patient was treated in the hospital as a stroke patient for five days and discharged with stroke medications.
After discharge, on the second day, the patient has the same previous symptoms.
Discussion: There was no proof of any other conceivable physiological, infective, naturally occurring, or other pathologic causes of dysarthria, save losartan itself.
A clinical pharmacist discovered adverse drug reaction probability It was "probable" that oral losartan caused the development off fainting and dysarthria in this patient.
The drugs for hypertension were changed by the clinical pharmacist to amlodipine 5mg.
After 3 days, the patient was stable, and the symptoms resolved.
Conclusions: This case report suggests that losartan could induce faintness and dysarthria as side effects.
Related Results
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Abstarct
Introduction
Isolated brain hydatid disease (BHD) is an extremely rare form of echinococcosis. A prompt and timely diagnosis is a crucial step in disease management. This ...
Speech, communication, and neuroimaging in Parkinson's disease : characterisation and intervention outcomes
Speech, communication, and neuroimaging in Parkinson's disease : characterisation and intervention outcomes
<p dir="ltr">Most individuals with Parkinson's disease (PD) experience changes in speech, voice or communication. Speech changes often manifest as hypokinetic dysarthria, a m...
Speech, communication, and neuroimaging in Parkinson's disease : characterisation and intervention outcomes
Speech, communication, and neuroimaging in Parkinson's disease : characterisation and intervention outcomes
<p dir="ltr">Most individuals with Parkinson's disease (PD) experience changes in speech, voice or communication. Speech changes often manifest as hypokinetic dysarthria, a m...
Speech, communication, and neuroimaging in Parkinson's disease : Characterisation and intervention outcomes
Speech, communication, and neuroimaging in Parkinson's disease : Characterisation and intervention outcomes
<p dir="ltr">Most individuals with Parkinson's disease (PD) experience changes in speech, voice or communication. Speech changes often manifest as hypokinetic dysarthria, a m...
Cometary Physics Laboratory: spectrophotometric experiments
Cometary Physics Laboratory: spectrophotometric experiments
<p><strong><span dir="ltr" role="presentation">1. Introduction</span></strong&...
A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension
A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension
Background: Candesartan is a relatively novel antihypertensive agent of the angiotensin receptor blocker (ARB). Several clinical trials have compared candesartan with losartan in t...
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract
Introduction
Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Renal clinical pharmacy services and outcomes for patients on dialysis: a scoping review
Renal clinical pharmacy services and outcomes for patients on dialysis: a scoping review
AbstractBackgroundPeople with end‐stage kidney disease receiving dialysis in any form commonly experience symptoms associated with their reduced renal function and dialysis treatme...

